Cibus (CBUS) Risk Assessment

View and export this data going back to 2017. Start your Free Trial

What is Cibus Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Cibus is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Cibus's Risk Assessment

For the Biotechnology subindustry, Cibus's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cibus's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cibus's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Cibus's Risk Assessment falls into.

Cibus (NAS:CBUS) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Cibus Risk Assessment Related Terms

Thank you for viewing the detailed overview of Cibus's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Cibus (CBUS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cibus Inc (NAS:CBUS) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

6455 Nancy Ridge Drive, San Diego, CA, USA, 92121

Website

https://www.cibus.com

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies.

Executives

Rory B Riggs	director, officer: Chief Executive Officer	65 RAILROAD AVE, RIDGEFIELD NJ 07657
Collins James C. Jr.	director	1007 MARKET STREET, D-9058, WILMINGTON DE 19898
Jonathan Finn	10 percent owner	C/O VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Gerhard Prante	director	SCHONE AUSSICHT 5, HOFHEIM A. TS 2M 65719
Mark Terrence Finn	director	VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Jean-pierre Jules Lehmann	director	21 ALPINASTRASSE, CH 3780, GSTAAD V8 3780
Keith Allen Walker	director	13315 ROXTON CIRCLE, SAN DIEGO CA 92130
Wade Hampton King	officer: Chief Financial Officer	750 MEADOWOOD DRIVE, ASPEN CO 81611
Gocal Gregory Francis William	officer: See Remarks	13737 BASSMORE DR., SAN DIEGO CA 92129
Peter Beetham	director, officer: See Remarks	6455 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Yves J Ribeill	director	C/O CALYXT, INC., 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Michael A. Carr	director, officer: President and CEO	2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
William Koschak	officer: Chief Financial Officer	2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Sarah Reiter	officer: Chief Business Officer	202 COUSTEAU PLACE, DAVIS CA 95618
Daniel F Voytas	officer: Chief Science Officer	2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113